𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Does ursodeoxycholic acid therapy alter the profile of the liver transplant recipient with primary biliary cirrhosis?

✍ Scribed by Gordon, Fiona; Muiesan, Paolo; Portmann, Bernard C.; Knisely, Alex S.; O'Donoghue, John; Rela, Mohammed; Heaton, Nigel D.; O'Grady, John G.

Book ID
121991316
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
345 KB
Volume
124
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effect of pretransplantation ursodeoxych
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis
✍ Heathcote, E. Jenny ;Stone, Julie ;Cauch-Dudek, Karen ;Poupon, Raoul ;Chazouille πŸ“‚ Article πŸ“… 1999 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 42 KB πŸ‘ 1 views

As ursodeoxycholic acid (UDCA) delays the need for transplantation, this could result in patients with more comorbid disease, therefore more likely to have a worse outcome posttransplantation. The aim of this study is to compare posttransplantation outcome in patients who received UDCA versus placeb

Does antimitochondrial antibody status a
Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation
✍ W R Kim; J J Poterucha; R A Jorgensen; K P Batts; H A Homburger; E R Dickson; R πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 270 KB πŸ‘ 2 views

rum. 1 In the past decade, two treatment modalities have Approximately 5% to 10% of patients with features otherbeen shown to be effective in the treatment for PBC, dewise consistent with primary biliary cirrhosis (PBC) lack antipending on the stage of the disease. For patients with less mitochondri